(1916-2008)
************************************************************************
1906
M orre B
1932
i ncret i n
f act or
1960 1964- 1967 1971
G IP
pol ypept i de ,
gast ri c i nhi bi t ory gl ucose- dependent
i nsul i notropi c pol ypept i de , 1985 -1
G LP- 1
gl ucagon l i ke pept i de- 1
Intestinal GLP-1 Release GLP-1(7-36) Active
Mixed Meal
GLP-1
DPP-4
D PP 4
t1/2 = 1-2 Minutes Rapid Inac tivation (>80% of Pool)
GLP-1(9-36) Inactive > 0 2 D ; 6 = P L G
(
( 3 C 4 : 8 ; -
) )
(
)
(
(
)
)
(
(
)
)
GLP-1 (
(
)
(
)
)
1.Daniel J.Drucker: The biology of inretin hormones, Cell Metabolism;2006:3:153165. 2.Daniel J Drucker, Michael A Nauck: The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl
peptidase-4 inhibitors in type 2 diabetes: Lancet 2006;368:1696-705. 3.Timothy S. Reid: Practical use of glucagons-like peptide-1 receptor agonist therapy in primary care. Clinical Diabetes 2013;31:148-157. 4.Mansur Shomaili: Optimizing the care of patients with type 2 diabetes using incretin-based therapy: focus on GLP-1 receptor agonists.Clinical Diabetes:2014;32(1):32-43.
1. Joe Murphy (2012-05-18). "Baroness Warsi: Some Pakistani men think young white girls are "fair game" for sex abuse - Politics - News - Evening Standard". Thisislondon.co.uk. Retrieved 2012-06-02. 2. Jump up ^ Abuse Scandal Plagues Hasidic Jews In Br ooklyn by Barbara Bradley Hagerty. All Things Considered, National Public Radio. 2 February 2009. 3.Amy, Neustein, ed. (2009). Tempest in the Temple: Jewish Communities and Child Sex Scandals. Brandeis Series in American Jewish History, Culture, and Life. Waltham, Massachusetts:
Brandeis University Press. ISBN 9781-58465-671-5. 4. Messman-Moore, Terri L.; Long, Patricia J. (2000). "Child Sexual Abuse and Revictimization in the Form of Adult Sexual Abuse, Adult Physical Abuse, and Adult Psychological Maltreatment". Journal of Interpersonal Vi o l e n c e 1 5 ( 5 ) : 4 8 9 – 5 0 2 . doi:10.1177/088626000015005003. 5.Widom C.S. (1999). "Post-traumatic stress disorder in abused and neglected children grown up," American Journal of Psychiatry; 156(8):1223-1229.
************************************************************************
1.Myburgh JA, Finfer S, Bellomo R, Billot L, Cass A, Gattas D, Glass P, Lipman J, Liu B, McArthur C et al: Hydroxyethyl Starch or Saline for Fluid Resuscitation in Intensive Care. New England Journal of Medicine, 367(20):1901-1911. 2.Zarychanski R A-SAMTAF, et al.: Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume r es u s c ita t io n : A s y ste m a ti c review and meta-analysis. JAMA, 309(7):678-688. 3.FDA: Hydroxyethyl Starch Solutions: FDA Safety Communication - Boxed Warning on Increased Mortality and Severe Renal Injury and Risk of Bleeding. h t t p : / / w w w. f d a . g o v / S a f e t y / MedWatch/SafetyInformation/Safe tyAlertsforHumanMedicalProduct s/ucm358349.htm.
4. Committee TEMAsPRA: PRAC recommends suspending marketing authorisations for infusion solutions containing hydroxyethyl starch. http://wwwemaeuropaeu/ ema/indexjsp curl=pages/news_ and_events/news/2013/06/news_d etail_001814jsp&mid=WC0b01ac 058004d5c1. 5.Perner A, Haase N, Guttormsen AB, Tenhunen J, Klemenzson G, MH, Elkj r JM, Poulsen LM et al: Hydroxyethyl Starch 130/0.42 versus Ringer's Acetate in Severe Sepsis. New England Journal of Medicine, 367(2):124-134. 6.Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, Moerer O, Gruendling M, Oppert M, Grond S et al: Intensive Insulin Therapy and Pentastarch Resuscitation in Severe Sepsis. New England Journal of Medicine 2008, 358(2):125-139.
1.Chung-Hsieh Su, Ken-Pen Weng, JiaKan Chang, Chu-Chuan Lin, Yu-Tung Hwang, Cheng-Liang Lee, KwanYen Chien, Chin-Kong Yu, WangShong Liu, Ta-Cheng Huang, KaiSheng Hsieh. Assessment of atrial septal defect- role of real-time 3D color Doppler echocardiography for interventional cathterization. Acta Cardiol Sin: 2005; 21:146-52. 2.Huang TC, Hsieh KS, Lin CC, Lee CL. Clinical results of percutaneous closure of large secundum atrial septal defects in children using the Amplatzer septal occluder. Heart Vessels. 2008;23:187-92. 3.Bartakian S, Fagan TE, Schaffer MS, Darst JR. Device closure of secundum atrial septal defects in children <15
kg: complication rates and indications for referral. JACC Cardiovasc Interv. 2012;5:1178-84. 4.Abaci A, Unlu S, Alsancak Y, Kaya U, Sezenoz B. Short and long term complications of device closure of atrial septal defect and patent foramen ovale: meta-analysis of 28,142 patients from 203 studies. Catheter Cardiovasc Interv. 2013;82:1123-38. 5.Medford BA, Taggart NW, Cabalka AK, Cetta F, Reeder GS, Hagler DJ, Johnson JN. Intrac ar diac Echocardiography during Atrial Septal Defect and Patent Foramen Ovale Device Closure in Pediatric and Adolescent Patients. J Am Soc Echocardiogr. 2014 ;27:984-90.
************************************************************************
************************************************************************